What is Celularity?
Celularity Inc. operates at the intersection of biotechnology and advanced medicine, focusing on the development of off-the-shelf cell therapy product candidates. The company utilizes mesenchymal-like adherent stromal cells to target high-unmet-need conditions, including Crohn's disease, diabetic foot ulcers, and facioscapulohumeral muscular dystrophy. Through its integrated business model, which spans Cell Therapy, Degenerative Disease research, and BioBanking, Celularity is uniquely positioned to transform the standard of care for aging-related and chronic illnesses. Its commitment to innovation in allogeneic cell manufacturing allows for scalable, standardized therapeutic solutions that bypass the limitations of traditional autologous treatments.
How much funding has Celularity raised?
Celularity has raised a total of $285.1M across 6 funding rounds:
Unspecified
$250M
Multiple Rounds
$21.8M
Other Financing Round
$13.3M
Unspecified (2018): $250M with participation from the Dreyfus Family Office, United Therapeutics, Human Longevity, Heritage Group, Celgene, Genting Berhad, Section 32, and Sorrento Therapeutics
Private Equity (2025): $1M, investors not publicly disclosed
Debt (2025): $6.8M, investors not publicly disclosed
Private Equity (2025): $2M, investors not publicly disclosed
Debt (2025): $12M, investors not publicly disclosed
Other Financing Round (2026): $13.3M with participation from NEXGEL
Key Investors in Celularity
United Therapeutics
Unither Pharmaceuticals is a global contract development and manufacturing organization specializing in the production of single-dose liquid pharmaceuticals and sterile unit-dose formats for the pharmaceutical and consumer healthcare industries.
Human Longevity
Human Longevity, Inc. is a global leader in advancing precision medicine in the pursuit of healthy aging and longevity medicine, supporting growth across international markets.
NEXGEL
NEXGEL is a healthcare and materials science company that develops and manufactures advanced hydrogel-based patches and transdermal delivery systems used in wound care and medical applications.
What's next for Celularity?
With the recent influx of capital, Celularity is poised to accelerate its clinical pipeline and expand its manufacturing capabilities. The strategic focus will likely shift toward optimizing the commercialization of its lead product candidates while strengthening its BioBanking infrastructure. As the company navigates the complexities of late-stage clinical trials, the continued support from institutional partners will be critical in maintaining its competitive edge in the global regenerative medicine market. Future growth will be defined by the successful transition of its therapeutic programs into the clinical market, further validating the efficacy of its placental-derived technology in treating systemic degenerative conditions.
See full Celularity company page
